Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, we aim to translate extraordinary science into life-changing therapies for patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/18/18 | $40,000,000 | Series A |
Atlas Venture EcoR1 Capital The Column Group | undisclosed |
| 04/23/20 | $63,000,000 | Series B |
AbbVie Biotech Ventures Atlas Venture DROIA Oncology Ventures EcoR1 Capital  GV NS Investment The Column Group The Mark Foundation for Cancer Research | undisclosed |
